$13.95
0.36% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US05463X1063
Symbol
AXGN

AxoGen, Inc. Stock price

$13.95
-0.36 2.52% 1M
+7.39 112.65% 6M
+7.12 104.25% YTD
+10.34 286.43% 1Y
-1.27 8.34% 3Y
+0.87 6.65% 5Y
+11.22 410.99% 10Y
Nasdaq, Closing price Fri, Nov 01 2024
-0.05 0.36%
ISIN
US05463X1063
Symbol
AXGN
Sector

Key metrics

Market capitalization $611.43m
Enterprise Value $653.33m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.77
P/S ratio (TTM) P/S ratio 3.52
P/B ratio (TTM) P/B ratio 6.39
Revenue growth (TTM) Revenue growth 17.26%
Revenue (TTM) Revenue $173.48m
EBIT (operating result TTM) EBIT $-12.21m
Free Cash Flow (TTM) Free Cash Flow $-13.67m
Cash position $27.13m
EPS (TTM) EPS $-0.38
P/E forward negative
P/S forward 3.31
EV/Sales forward 3.54
Short interest 3.33%
Show more

Is AxoGen, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

AxoGen, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a AxoGen, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a AxoGen, Inc. forecast:

Buy
100%

Financial data from AxoGen, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
173 173
17% 17%
100%
- Direct Costs 39 39
47% 47%
22%
135 135
11% 11%
78%
- Selling and Administrative Expenses 112 112
2% 2%
64%
- Research and Development Expense 28 28
2% 2%
16%
-4.99 -4.99
75% 75%
-3%
- Depreciation and Amortization 7.22 7.22
52% 52%
4%
EBIT (Operating Income) EBIT -12 -12
51% 51%
-7%
Net Profit -17 -17
30% 30%
-10%

In millions USD.

Don't miss a Thing! We will send you all news about AxoGen, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AxoGen, Inc. Stock News

Neutral
GlobeNewsWire
about 2 months ago
ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®.
Neutral
Seeking Alpha
3 months ago
AxoGen, Inc. (NASDAQ:AXGN ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Harold Tamayo - Vice President-Finance and Investor Relations Karen Zaderej - Chairman, Chief Executive Officer and President Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Catlin Cronin - Canaccord Genuity Jay...
Neutral
GlobeNewsWire
3 months ago
ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Michael Dale is appointed as chief executive officer and as a member of the Axogen Board of Directors effective August 9, 2024. He succeeds Karen Zaderej, who will remain in an ...
More AxoGen, Inc. News

Company Profile

AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Head office United States
CEO Michael Dale
Employees 428
Founded 1977
Website www.axogeninc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today